摘要
目的 研究c-myc基因在胸腺瘤组织中的表达，探讨c-myc基因与胸腺瘤的发生发展、恶性程度的关系。方法 应用免疫组织化学SP法，检测c—myc在41例胸腺瘤和18例非肿瘤胸腺组织中的表达，结合胸腺瘤WHO分型、Masaoka分期，研究c-myc基因在胸腺瘤各分型、分期中的表达情况。结果 c-myc在胸腺瘤中的阳性表达率为63．4％，在非肿瘤胸腺组织中的阳性表达率为16．7％，两者间有统计学差异（P〈0．01）。c-myc在良性胸腺瘤（A／AB型）和恶性胸腺瘤（B1～B3型）中的表达分别为30．0％和74．2％，两者有统计学差异（P〈0．05）。c-myc在非侵袭性胸腺瘤（Ⅰ期）与侵袭性胸腺瘤（Ⅱ～Ⅳ期）中的表达分别为33．3％和75．9％，两者有统计学差异（P〈0．05）。结论 c-myc与胸腺瘤的发生发展有关；与胸腺瘤的恶性程度、侵袭性有关。
Objective To correlate the expression of c-myc in the thymomas with histological type, clinical stage. Methods c-myc＇s expression in paraffin-embedded sections of 41 thymomas and 18 non-neoplastic thymus were detected by immunohistochemical SP assay. Results The positive rates of c-myc in thy momas and non neoplastic thymus was 63.4% （26/41）, 16. 7% （3/18）. And the different was significant （P〈0. 01 ）. The difference of c-myc positive rate in thymomas was significant between WHO histological type A/AB （30.0%） and type B （74.2%）（P〈0.05）. The positive rate of c myc in thymomas of Masaoka clinical stage Ⅱ-Ⅳ （75.9%） was significantly higher than that of stage Ⅰ （3.3.3%）（P〈 0.05）. Conclusion c-myc may play an important role in the occurrence and development of thymoma. Testing the expression of c-myc in thymomas will be helpful to predict the aggression and prognosis.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2006年第12期865-867,共3页
Cancer Research on Prevention and Treatment
